retatrutide diabetes trial FDA Approval Status 2026: Everything We Know So Far ESC 2024: Retatrutide improves lipid

Cure P, Pileggi A, Alejandro R

available evidence is limited to a single Phase 2 trial, and access should only be sought through registered clinical trials

You can also report suspected side effects to the MHRA through the Yellow Card scheme at yellowcard.mhra.gov.uk

10.2337/diabetes.51.2007.s434 [DOI] [PubMed] 57.Park S, Dong X, Fisher TL, et al

Fifth, cost-effectiveness analyses are critical given the high price of current GLP-1 RAs and the large potential treatment population: preliminary health-economic models suggest acceptable cost-effectiveness ratios in high-fibrosis patients with comorbid type 2 diabetes and cardiovascular disease, but robust data in broader MASLD populations are lacking

These numbers exceed every other obesity medication currently available or in development